CLINICAL_TRIALS
trial_result
· 2020-11-23
Clinical Trial Update: Study of Efficacy of PEAR-004 in Schizophrenia [Phase 2]
Summary
Phase 2 trial update for PEAR-004 in schizophrenia; study completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2020-11-23